170 results about "TLR4" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of Ackerman muciniphila in preparation of diabetic metabolic disease related renal injury products. The preservation number of the ackermann muciniphile is CGMCC (China General Microbiological Culture Collection Center) No.20955. The ackermann muciniphile provided by the invention can be used for remarkably reducing the indexes of blood urea nitrogen, serum creatinine and urine protein and improving the renal function; the oxidative stress of the kidney is relieved by reducing the malondialdehyde level and improving the activity of SOD, CAT and GSH-Px; the TLR4 / NF-kappa B pathway is inhibited, TNF-alpha and IL-1beta secretion is reduced, and inflammatory response is relieved; finally, the kidney protection effect is achieved through the anti-oxidation, anti-inflammatory and anti-fibrosis effects.

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

The invention belongs to the technical field of animal immunopotentiators, and particularly relates to an oil-in-water type veterinary adjuvant and a preparation method thereof. The oil-in-water type veterinary adjuvant comprises white oil, span 80, Tween 80, PEG400, astragalus polysaccharide and a phosphate buffer solution, the astragalus polysaccharide cooperates with a surfactant to activate a TLR4 / NF-kappa B pathway, Th1 / Th2 / Th17 three-way immune response is achieved, the serum IgG and mucous membrane sIgA antibody level is remarkably improved, and the problems that a traditional O / W adjuvant is high in layering rate (smaller than 5%), and the stability of the traditional O / W adjuvant is poor are solved through compound optimization of the HLB value (HLB = 11.5-12.0) of the HLB value of span 80 and Tween 80. And storage at 4 DEG C for 90 days) and poor freeze-thaw stability are solved.

The invention relates to an establishment method and application of in-vitro intestinal inflammation models of mice of different ages, and relates to the technical field of biology. According to the invention, young, adult, middle-aged and old wild type (WT) and TLR4 gene deletion type (TLR4 <- / ->) mice are selected, colon tissues are cultured in vitro, inflammatory response is induced by using interleukin-1beta (IL-1beta) stimulation, an age-related intestinal inflammation model is constructed, the inflammation phenotype of the mouse model and the activity of a TLR4 / MyD88 / NF-kappa B signaling pathway are determined by comparing WT and TLR4 <- / ->, and the age-related intestinal inflammation model is constructed. The core function of the TLR4 in regulating age-dependent intestinal barrier dysfunction is defined, a regulatory network of the TLR4 in intestinal immune aging and flora-host interaction is disclosed, and an age personalized medical strategy is promoted. According to the invention, an efficient and customizable multi-age in-vitro intestinal inflammation model is constructed, and an innovative platform is provided for mechanism analysis and intervention drug screening of TLR4 targeted therapy and age-related intestinal diseases.

The invention belongs to the technical field of food biology, and discloses an abalone-derived immunomodulatory peptide as well as a preparation method and application thereof. The abalone source immunomodulatory peptide is obtained by combining double-enzyme enzymolysis and molecular docking screening, and comprises at least one of peptides with amino acid sequences shown as SEQ.ID.NO.1-6, and the docking energy of the peptides and a receptor TLR4 is-7.4 kcal / mol,-6.9 kcal / mol,-6.8 kcal / mol,-6.8 kcal / mol,-6.8 kcal / mol and-6.6 kcal / mol in sequence respectively. Experiments prove that the abalone peptide has high immunocompetence, can provide a basis for application of the abalone-derived immunomodulatory peptide in preparation of functional food from natural food sources, and has important significance for development of novel immunomodulatory peptide products.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.

The invention relates to the technical field of medicinal chemistry, and provides a TLR4 agonist, application thereof and a vaccine composition. The TLR4 agonist is a compound with a structure as shown in a formula 1 or a pharmaceutically acceptable salt thereof, the compound is glucosamine aminoalkyl 4-phosphate series molecules derived from MPL-12 structure modification, and the series molecules have enhanced immunostimulatory activity and selective immune response induction capability.

The invention belongs to the technical field of traditional Chinese medicine research, and particularly relates to ganoderma lucidum polysaccharide and an extraction method and application thereof. The structural formula of the ganoderan is shown as a formula I in the specification. The ganoderan extracted by the invention can repair intestinal barriers by promoting the growth of beneficial intestinal bacteria, alleviate liver inflammation by targeting LPS / TLR4 / NF-kappa B / MAPK signal pathways, and reduce fat accumulation, thereby effectively alleviating the non-alcoholic fatty liver disease; and # imgabs0 #.

The invention discloses application of hesperidin in preparation of a medicine for preventing and / or treating porcine contagious pleuropneumonia, and belongs to the field of biological medicine. The concentration of the hesperidin is 6.25-25 [mu] g / mL, and cell experiments prove that the hesperidin can inhibit cell inflammatory response and reduce expression of inflammatory factors, and can effectively relieve the actinobacillus pleuropneumoniae induced endovascular dermatitis injury by inhibiting activation of CD14 / TLR4-NF [kappa] B P65. Animal experiments prove that the hesperidin can relieve pathological changes and injuries of various tissues and organs after actinobacillus pleuropneumoniae infection, improve weight loss caused by actinobacillus pleuropneumoniae infection, relieve inflammatory response and metabolic dysfunction caused by actinobacillus pleuropneumoniae, and improve the body weight loss caused by actinobacillus pleuropneumoniae. The composition plays a role in protecting organisms infected by actinobacillus pleuropneumoniae. The invention provides a new scientific basis for controlling porcine contagious pleuropneumonia by using natural medicines.

The application discloses a virtual screening method of a small-molecule compound targeting TLR4. The application screens potential compounds capable of combining with TLR4 through three-dimensional molecular docking, and preliminarily proves that three compounds, Z1410232649, F27210326 and HY-N0029, have better TLR4 inhibiting effects through experimental verification. Among them, Z1410232649 performs most outstandingly, can significantly inhibit the release of inflammatory factors IL-6, TNF-alpha and IFN-gamma induced by LPS, and can be used as a novel anti-inflammatory drug or immunotherapy drug targeting TLR4.

The invention discloses a Chinese forest frog peptide or a salt thereof. The Chinese forest frog peptide comprises an amino acid sequence Asn-Pro-Asp-Tyr-Arg as shown in SEQ ID NO: 1. Moisturizing and relieving mechanisms of the peptide are explored through molecular docking, and we find that the Chinese forest frog peptide as shown in SEQ ID NO: 1 can be effectively docked with hyaluronidase and TLR4-MD2. According to the present invention, chemical synthesis and activity evaluation are performed on the Chinese forest frog peptide Asn-Pro-Asp-Tyr-Arg (NPDYR) represented by SEQ ID NO: 1, and the Chinese forest frog peptide shows certain repairing, moisturizing and soothing activities, can be used as a functional component in cosmetics, and has good application prospects.

The invention provides application of PRP-Exos in preparation of a medicine for treating neuropathic pain, and relates to the technical field of clinical medicine. According to the invention, the treatment effect of PRP-Exos on neuropathic pain by inhibiting a TLR4 / NF-kappa B signal channel is clarified, a new thought is provided for clinical transformation, meanwhile, an intrathecal injection delivery mode is adopted, the limitation of low bioavailability of peripheral administration is overcome, meanwhile, the treatment effect is comprehensively verified through a behavioral-histological-molecular biological multi-modal evaluation system, and the application prospect is wide. The potential of the PRP-Exos in relieving the neuropathic pain is proved.

This invention provides the use of Yigongsan in the treatment of myelodysplastic syndrome (MDS). Specifically, this invention has found that Yigongsan improves ineffective hematopoiesis in MDS patients and significantly alleviates traditional Chinese medicine symptoms of MDS, such as fatigue, lethargy, lack of thirst, and sallow complexion. Furthermore, it has been discovered that Yigongsan regulates hematopoietic function in MDS through the S100A9-TLR4-NF-κB signaling pathway. This invention also provides a treatment method for MDS.

The invention discloses a manganese-based nano-enzyme composite material as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) preparing Mn3O4-PVP from Mn3O4 NPs and PVP10, and then loading the Mn3O4-PVP into a ZIF-8 structure in the process that Zn < 2 + > and 2-MI react to form ZIF-8, so as to obtain Mn3O4-coated ZIF-8 NPs; (2) covering the surface of the Mn3O4 ZIF-8 with HA through ion coordination, and synthesizing MZH; and (3) carrying out clathration on MZH through ES100, and synthesizing MZH coated ES100. By inhibiting a TLR4 / NF-kappa B pathway, activating an Nfr2 / Keap1 pathway and increasing expression of intestinal tight junction protein, mouse colitis induced by DSS is resisted, and symptoms of the mouse colitis are relieved.

The application discloses application of Bifidobacterium longum exopolysaccharide or a co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and probiotics in improving inflammation. The application finds that the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can inhibit LPS-induced TLR4 / NfkB (P65) signal path activation, inhibit the polarization of macrophages from M0 to M1, thereby inhibiting inflammatory reactions, and the inhibiting effect of the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus is more obvious. Therefore, the Bifidobacterium longum exopolysaccharide and the co-incubation extractive solution of the Bifidobacterium longum exopolysaccharide and Lactobacillus acidophilus can be used for preparing drugs for inhibiting inflammatory reactions, and are helpful to the treatment of immune and chronic inflammatory diseases and the development of related drugs.

The application discloses an application of a TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, relates to the technical field of biology and medicine, and discloses an application of the TLR4 / NF-kappa B signal path inhibitor in preparation of a medicine for improving hematopoietic function of anemic inflammatory, wherein the TLR4 / NF-kappa B signal path inhibitor is Danggui Buxue Decoction; the Danggui Buxue Decoction is composed of Astragalus and Angelica with a mass ratio of 5:1; the TLR4 / NF-kappa B signal path inhibitor is used for down-regulating expression of TLR4 protein and NF-kappa B protein in liver tissue; the improvement of hematopoietic function of anemic inflammatory includes increasing peripheral blood red blood cell count, white blood cell count, platelet count and hemoglobin level; the Danggui Buxue Decoction is used as the TLR4 / NF-kappa B inhibitor to improve anemic inflammatory, can down-regulate TLR4 / NF-kappa B expression, improve blood cells and hemoglobin, improve bone marrow pathology, reduce inflammatory factors and hepcidin, increase iron content, and provide a corresponding curative effect evaluation method, and provides a new choice for anemic inflammatory treatment.

The invention discloses application of tenuifolin in preparation of a medicine for treating multiple sclerosis, and belongs to the technical field of biological pharmacy. Aiming at the problem that the treatment effect and the specific action mechanism of TEN on the multiple sclerosis disease are not clear yet, an EAE model group of a mouse is used for simulating the multiple sclerosis disease, meanwhile, a TEN intervention group is set for simulating the multiple sclerosis disease and then TEN intervention is carried out, and it can be found through experimental comparison that compared with mice of the EAE model group, the mice of the TEN intervention group are more obvious in effect. The average neurological function score is obviously reduced, the clinical symptoms and the demyelination degree are alleviated, the MBP expression is increased, and the inflammatory infiltration is reduced; in addition, TEN intervention can significantly reduce the increase of TLR4 / NF-kappa B protein in mouse spinal cord tissues of an EAE model group. The TEN can inhibit activation of a TLR4 / NF-kappa B pathway to effectively relieve demyelination and abnormal behaviors of mice of an EAE model group and slow down inflammatory response, so that the TEN plays a role in treating the mice of the EAE model group.

The invention belongs to the technical field of novel application of nattokinase, and provides application of nattokinase in preparation of a medicine for preventing and / or treating Parkinson's disease. According to the invention, an MPTP / MPP + induced Parkinson's disease (PD) in-vivo and in-vitro model is established, and a neuroprotection mechanism of nattokinase is disclosed by adopting a systematic experiment method. Results show that the nattokinase can significantly improve dyskinesia and intestinal dysfunction of MPTP-induced PD mice; the damage of dopaminergic neurons of the middle brain is effectively relieved, and the density of tyrosine hydroxylase positive neurons is maintained; the expression of TLR4 and NLRP3 inflammasome pathways and related proinflammatory cytokines is inhibited, and the neuroinflammatory response is relieved; pINK1 / Parkin expression is up-regulated, mitochondrial autophagy is activated, and damaged neurons are cleared. Direct association between nattokinase and Parkinson's disease prevention and treatment is established for the first time, an innovative solution is provided for developing a novel anti-Parkinson's disease medicine with dual effects of motor function improvement and neuroprotection, and the application has important development value in the field of treatment of neurodegenerative diseases.

The invention belongs to the field of polypeptides, and particularly relates to a TLR4 binding peptide and application thereof. The specific technical scheme is as follows: the nucleotide sequence of the polypeptide is edited as shown in SEQ ID NO: 1. The binding peptide containing 67 amino acids is screened out, is good in solubility, can be stably bound with TLR4, and is expected to become a new medicine for treating or relieving pain including chronic pain. The polypeptide can also be prepared into health care products, special medical foods and the like with the function of treating or relieving pain according to actual conditions.

The present disclosure relates to the use of compound (I) and any of its salts for the treatment of a neoplasm characterized by high expression of toll-like receptor 4 (TLR4) in the tumor or its microenvironment, associated with at least one of the pathophysiological complications including immunosuppression, angiogenesis, fibrosis, or metastasis.

The invention provides lactobacillus plantarum S7-12, fermented vegetables and application of the lactobacillus plantarum S7-12 and the fermented vegetables, and belongs to the technical field of microbial fermentation, the lactobacillus plantarum S7-12 is preserved in Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66578. The plant lactobacillus S7-12 has relatively strong growth ability, acid production ability, acid resistance and salt resistance, and fermented vegetables prepared from the plant lactobacillus S7-12 can be used for relieving weight loss and colon shortening caused by inflammatory bowel diseases, reducing disease activity indexes and visceral organ indexes, relieving intestinal mucosa structural damage, relieving oxidative stress injury of colon, and improving the immunity of the vegetables. The release of proinflammatory factors in serum and colon is reduced, the secretion of anti-inflammatory factors is improved, the expression quantity of colon tight junction protein is increased, the TLR4 pathway is activated, and the colon barrier function is improved; the method can be used for preparing health-care foods or medicines, and has a wide application prospect.

Stable aqueous formulations of adjuvant comprising a TLR7 / 8 agonist or a TLR4 agonist with a helper lipid that are adsorbed to alum are provided. Compositions and methods of using the formulations for stimulating an immune response are also provided.

The invention belongs to the field of medicine detection, and particularly discloses a comprehensive control method for the quality of compound Pien Tze Huang lozenges, which comprises the following steps of: fishing targeted protein active ingredients of the compound Pien Tze Huang lozenges by respectively adopting a surface plasma resonance instrument with a built-in TNFR2 protein chip, a built-in TLR4 protein chip or a built-in TLR5 protein chip; the biological effect of the compound Pien Tze Huang lozenge is detected by adopting an SPR method based on the fished anti-inflammatory active ingredients, and the fingerprint spectrum of the compound Pien Tze Huang lozenge and the content of the ingredients in the fingerprint spectrum are detected by adopting an UPLC method. The surface plasmon resonance method and the UPLC method are combined to control the quality of the compound Pien Tze Huang lozenge, evaluation of the overall drug effect and accurate determination of component composition are combined, the quality of the compound Pien Tze Huang lozenge is controlled more comprehensively, and the method has practical application value.

The invention discloses a novel immune enhancement system, which comprises a specific TLR4 agonistic polypeptide and a CD40 single-domain antibody. According to the polypeptide, a KLAKLAK core module is adopted, penetrating peptide and hydrophobic groups are modified, and an NF-kappa B / MAPK pathway can be effectively activated; the antibody is obtained through shark immune screening and has high affinity to CD40. When in combined application, the GM-CSF / IL-4-containing medium synergistically promotes the maturation of dendritic cells, so that the expression of CD80 / CD86 / MHC-II is improved by more than 2 times, the secretion amount of IL-12 reaches 165 pg / mL, and the proliferation rate of T cells is improved to 48.6%. Animal experiments show that the T cell stimulation index of a combined group reaches 6.2, and the serum IFN-gamma level is improved by 9 times. The composition provided by the invention can significantly enhance the DC vaccine efficacy, and has important application value in the field of tumor immunotherapy.

The invention discloses a traditional Chinese medicine composition for inhibiting salmonella choleraesuis as well as a preparation and application thereof, and belongs to the technical field of traditional Chinese medicine and network pharmacology. According to the invention, traditional Chinese medicines with a good antibacterial effect on S. Choletaesuis are screened, and the compound five-plum decoction with a good antibacterial effect on S. Choletaesuis is established. The five-plum decoction can be used for effectively regulating and controlling the steady state of intestinal flora, and reducing the oxidative damage and inflammatory damage of the S. Cholera to the intestinal tract and the liver by regulating and controlling the signal channels of TLR4 / NF-kB / MyD88 and ZO-1 / Claudin-1 / Occludin. Through the multiple effects of resisting bacteria, resisting inflammation, protecting intestinal barriers and improving production performance, the five-plum decoction shows remarkable prevention and treatment effects on swine paratyphoid, and has huge value of being developed into a novel veterinary traditional Chinese medicine preparation and put into clinical application.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

The invention relates to application of rosa rugosa in preparation of a medicine for treating IBD (infectious bursal disease). According to the invention, firstly, it is found that the branchlet rose has a repairing effect on damage caused by IBD; researches find that the aqueous extract of rugosa branchlet can play a role by repairing intestinal barriers and inhibiting TLR4, TLR9 and proinflammatory cytokines, so that the aqueous extract of rugosa branchlet is beneficial to treatment of IBD. The invention provides an application prospect of the rosa rugosa in preparation of the medicine for treating IBD.

The invention discloses a foot-and-mouth disease inactivated vaccine immunologic adjuvant composition. The foot-and-mouth disease inactivated vaccine immunologic adjuvant composition comprises a TLR4 agonist, a TLR9 agonist, an anionic surfactant and a cationic high-molecular polymer. The weight ratio of the TLR4 agonist to the TLR9 agonist to the cationic high-molecular polymer to the anionic surfactant is (50 to 150): (50 to 150): (800 to 1100): (1 to 5). The foot-and-mouth disease inactivated vaccine immunologic adjuvant composition provided by the invention not only can provide protective activity for foot-and-mouth disease antigens, but also has the advantages of fast antibody production and high antibody production level after animal immunization, so that animals can obtain good immune protection.

The invention provides an application of alkaloid bicuculline in preparation of a medicine for preventing and / or treating hepatic fibrosis diseases and hepatic inflammation, and also provides an application of bicuculline in preparation of an inflammatory factor expression inhibitor and an application of bicuculline in preparation of a Toll-like receptor 4 signal channel inhibitor. 7.5 mu g / mL of bicuculline can be used for relieving the activation of hepatic stellate cells induced by TGF-beta1, remarkably reducing the expression of alpha-SMA and COL1A1, and reducing the expression of MyD88 and NF-kB as well as downstream inflammatory factors IL-6, IL-1beta and TNF-alpha in a TLR4 / MyD88 / NF-kB signal channel. By intraperitoneal injection treatment of 0.6 mg / kg of bicuculline, the liver morphology in a fibrosis model can be remarkably improved, the levels of ALT and AST in serum can be remarkably reduced, and collagen deposition and expression of alpha-SMA and COL1A1 in the liver can be remarkably reduced.

The invention belongs to the technical field of gene engineering, and provides Hsp60 receptor targeted recombinant lactobacillus plantarum as well as a construction method and application thereof, lactobacillus plantarum is taken as a host, pPG612 is taken as an expression vector, and CsgB gene or CsgF gene is expressed. The two engineering probiotics can express target protein and can be stably expressed on the surfaces of thalli, the AB.9 intestinal epithelial cells can be effectively adhered, and the adhesion and invasion of the A.veronii to the AB.9 cells can be inhibited. And secondly, the engineering probiotics LP-pPG-CsgB and LP-pPG-CsgF can promote the proliferation of dendritic cells, T lymphocytes and B lymphocytes, and improve the IgT secretion of intestinal mucus. The engineering bacteria can be competitively combined with an intestinal epithelial cell Hsp60 receptor, down-regulate p65 expression, inhibit NF-kappa B signal channel activation, regulate intestinal tight junction protein redistribution and down-regulate proinflammatory factor expression through a TLR4 / TLR5 dependent NF-kappa B signal channel, and the engineering bacteria can increase the abundance of effective microbial communities in the intestinal tract of the snakeheaded fish, so that the growth of the snakeheaded fish is promoted, and the growth of the snakeheaded fish is promoted. And the flora can transfer, mediate and activate immune response through a feeding environment.